| Summary of making decisions regarding the allocation of resources and to assess performance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2025 |
|
|
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
(EUR thousand) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External customers |
|
|
1,038,174 |
|
|
|
148,108 |
|
|
|
1,186,282 |
|
|
|
— |
|
|
|
1,186,282 |
|
Inter-segment |
|
|
2,163 |
|
|
|
132,901 |
|
|
|
135,064 |
|
|
|
(135,064 |
) |
|
|
— |
|
Total revenue |
|
|
1,040,337 |
|
|
|
281,009 |
|
|
|
1,321,346 |
|
|
|
(135,064 |
) |
|
|
1,186,282 |
|
Cost of sales |
|
|
712,187 |
|
|
|
249,992 |
|
|
|
962,179 |
|
|
|
(119,773 |
) |
|
|
842,406 |
|
Gross Profit |
|
|
328,150 |
|
|
|
31,017 |
|
|
|
359,167 |
|
|
|
(15,291 |
) |
|
|
343,876 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
8,434 |
|
|
|
— |
|
|
|
8,434 |
|
|
|
(190 |
) |
|
|
8,244 |
|
Selling and marketing expenses |
|
|
23,568 |
|
|
|
2,691 |
|
|
|
26,259 |
|
|
|
1,960 |
|
|
|
28,219 |
|
Research and development expenses |
|
|
19,585 |
|
|
|
5,978 |
|
|
|
25,563 |
|
|
|
(127 |
) |
|
|
25,436 |
|
General and administrative expenses |
|
|
73,005 |
|
|
|
13,019 |
|
|
|
86,024 |
|
|
|
13,640 |
|
|
|
99,664 |
|
Operating Profit |
|
|
220,426 |
|
|
|
9,329 |
|
|
|
229,755 |
|
|
|
(30,954 |
) |
|
|
198,801 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of which amortization and depreciation and impairment of PPE |
|
|
84,687 |
|
|
|
3,484 |
|
|
|
88,171 |
|
|
|
394 |
|
|
|
88,565 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2024 |
|
|
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
(EUR thousand) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External customers |
|
|
933,742 |
|
|
|
170,294 |
|
|
|
1,104,036 |
|
|
|
— |
|
|
|
1,104,036 |
|
Inter-segment |
|
|
4,037 |
|
|
|
187,342 |
|
|
|
191,379 |
|
|
|
(191,379 |
) |
|
|
— |
|
Total revenue |
|
|
937,779 |
|
|
|
357,636 |
|
|
|
1,295,415 |
|
|
|
(191,379 |
) |
|
|
1,104,036 |
|
Cost of sales |
|
|
668,997 |
|
|
|
301,466 |
|
|
|
970,463 |
|
|
|
(168,746 |
) |
|
|
801,717 |
|
Gross Profit |
|
|
268,782 |
|
|
|
56,170 |
|
|
|
324,952 |
|
|
|
(22,633 |
) |
|
|
302,319 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
8,926 |
|
|
|
108 |
|
|
|
9,034 |
|
|
|
57 |
|
|
|
9,091 |
|
Selling and marketing expenses |
|
|
20,847 |
|
|
|
3,591 |
|
|
|
24,438 |
|
|
|
415 |
|
|
|
24,853 |
|
Research and development expenses |
|
|
23,292 |
|
|
|
7,308 |
|
|
|
30,600 |
|
|
|
1,068 |
|
|
|
31,668 |
|
General and administrative expenses |
|
|
67,933 |
|
|
|
12,284 |
|
|
|
80,217 |
|
|
|
13,530 |
|
|
|
93,747 |
|
Operating Profit |
|
|
165,636 |
|
|
|
33,095 |
|
|
|
198,731 |
|
|
|
(37,589 |
) |
|
|
161,142 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of which amortization and depreciation and impairment of PPE |
|
|
75,747 |
|
|
|
3,808 |
|
|
|
79,555 |
|
|
|
1,097 |
|
|
|
80,652 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2023 |
|
|
|
Biopharmaceutical
and Diagnostic
Solutions |
|
|
Engineering |
|
|
Total
segments |
|
|
Adjustments,
eliminations
and
unallocated
items |
|
|
Consolidated |
|
|
|
(EUR thousand) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External customers |
|
|
879,288 |
|
|
|
206,066 |
|
|
|
1,085,354 |
|
|
|
— |
|
|
|
1,085,354 |
|
Inter-segment |
|
|
2,049 |
|
|
|
166,741 |
|
|
|
168,790 |
|
|
|
(168,790 |
) |
|
|
— |
|
Total revenue |
|
|
881,337 |
|
|
|
372,807 |
|
|
|
1,254,144 |
|
|
|
(168,790 |
) |
|
|
1,085,354 |
|
Cost of sales |
|
|
591,107 |
|
|
|
294,550 |
|
|
|
885,657 |
|
|
|
(140,196 |
) |
|
|
745,461 |
|
Gross Profit |
|
|
290,230 |
|
|
|
78,257 |
|
|
|
368,487 |
|
|
|
(28,594 |
) |
|
|
339,893 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
10,630 |
|
|
|
16 |
|
|
|
10,646 |
|
|
|
(223 |
) |
|
|
10,423 |
|
Selling and marketing expenses |
|
|
20,970 |
|
|
|
3,948 |
|
|
|
24,918 |
|
|
|
60 |
|
|
|
24,978 |
|
Research and development expenses |
|
|
27,653 |
|
|
|
7,420 |
|
|
|
35,073 |
|
|
|
599 |
|
|
|
35,672 |
|
General and administrative expenses |
|
|
64,658 |
|
|
|
13,290 |
|
|
|
77,948 |
|
|
|
10,998 |
|
|
|
88,946 |
|
Operating Profit |
|
|
187,579 |
|
|
|
53,615 |
|
|
|
241,194 |
|
|
|
(40,474 |
) |
|
|
200,720 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of which amortization and depreciation and impairment of PPE |
|
|
75,320 |
|
|
|
3,821 |
|
|
|
79,141 |
|
|
|
(661 |
) |
|
|
78,480 |
|
|